CN106458869A - 具有免疫疾病治疗效果的新型化合物及其应用 - Google Patents

具有免疫疾病治疗效果的新型化合物及其应用 Download PDF

Info

Publication number
CN106458869A
CN106458869A CN201580021720.9A CN201580021720A CN106458869A CN 106458869 A CN106458869 A CN 106458869A CN 201580021720 A CN201580021720 A CN 201580021720A CN 106458869 A CN106458869 A CN 106458869A
Authority
CN
China
Prior art keywords
cells
disease
compound
cell
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580021720.9A
Other languages
English (en)
Chinese (zh)
Inventor
曹美罗
申東润
朴盛焕
梁哲宇
崔钟荣
朴潣廷
孙惠辰
李圣希
李善瑛
金恩敬
金在庚
李昇勋
朴星赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Catholic University of Korea
Original Assignee
Industry Academic Cooperation Foundation of Catholic University of Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of Catholic University of Korea filed Critical Industry Academic Cooperation Foundation of Catholic University of Korea
Priority to CN202010321725.6A priority Critical patent/CN111407753A/zh
Priority claimed from PCT/KR2015/004299 external-priority patent/WO2015167243A1/ko
Publication of CN106458869A publication Critical patent/CN106458869A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN201580021720.9A 2014-04-29 2015-04-29 具有免疫疾病治疗效果的新型化合物及其应用 Pending CN106458869A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010321725.6A CN111407753A (zh) 2014-04-29 2015-04-29 具有免疫疾病治疗效果的新型化合物及其应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020140051261 2014-04-29
KR10-2014-0051261 2014-04-29
PCT/KR2015/004299 WO2015167243A1 (ko) 2014-04-29 2015-04-29 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010321725.6A Division CN111407753A (zh) 2014-04-29 2015-04-29 具有免疫疾病治疗效果的新型化合物及其应用

Publications (1)

Publication Number Publication Date
CN106458869A true CN106458869A (zh) 2017-02-22

Family

ID=54601170

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010321725.6A Pending CN111407753A (zh) 2014-04-29 2015-04-29 具有免疫疾病治疗效果的新型化合物及其应用
CN201580021720.9A Pending CN106458869A (zh) 2014-04-29 2015-04-29 具有免疫疾病治疗效果的新型化合物及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010321725.6A Pending CN111407753A (zh) 2014-04-29 2015-04-29 具有免疫疾病治疗效果的新型化合物及其应用

Country Status (8)

Country Link
US (2) US20170114008A1 (enExample)
EP (1) EP3130582B8 (enExample)
JP (1) JP6462002B2 (enExample)
KR (1) KR101705446B1 (enExample)
CN (2) CN111407753A (enExample)
AU (1) AU2015254037B2 (enExample)
CA (1) CA2946516C (enExample)
ES (1) ES2702337T3 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111566084A (zh) * 2017-09-05 2020-08-21 北京强新生物科技有限公司 中枢神经系统疾病的新疗法
CN113194936A (zh) * 2018-11-07 2021-07-30 加图立大学校产学协力团 含新型化合物和钙调磷酸酶抑制剂的用于预防和治疗移植排斥反应或移植排斥疾病的组合物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101949451B1 (ko) 2015-10-13 2019-05-10 주식회사 이노파마스크린 염증성 장 질환 및 아토피 피부염 치료용 조성물
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
CN111936127A (zh) 2018-02-15 2020-11-13 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
EP3846792A4 (en) 2018-09-06 2022-10-12 Innopharmascreen Inc. METHODS AND COMPOSITIONS FOR TREATING ASTHMA OR PARKINSON'S DISEASE
EP3891179A4 (en) * 2018-12-04 2022-08-24 The Children's Medical Center Corporation METHODS AND COMPOSITIONS FOR THE TREATMENT OF ASTHMA
KR102316961B1 (ko) * 2020-01-29 2021-10-26 프라비바이오 주식회사 면역억제제로서의 벤젠 유도체의 면역억제용 약학적 조성물
CN113907047B (zh) * 2021-12-13 2022-03-11 天津医科大学总医院空港医院 一种自身抗原表位诱导的eam小鼠模型的建立方法
CN115152700B (zh) * 2022-06-28 2023-06-27 广东省人民医院 胶体锰佐剂在制备原发性干燥综合征动物模型中的应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060635A (en) * 1975-03-31 1977-11-29 William H. Rorer, Inc. Amidinoureas for treating diarrhea
US4183956A (en) * 1975-11-05 1980-01-15 William H. Rorer, Inc. Method for treating gastrointestinal spasms, gastrointestinal hyperacidity and hypertensive disorders with amidinoureas
WO2003084475A2 (en) * 2002-03-29 2003-10-16 University Of Maryland, Baltimore INHIBITORS OF THE S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF INHIBITING CANCER EMPLOYING THE SAME
WO2003089601A2 (en) * 2002-04-17 2003-10-30 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
US20110053941A1 (en) * 2007-11-30 2011-03-03 Newlink Genetics IDO Inhibitors
KR20110053837A (ko) * 2009-11-16 2011-05-24 한올바이오파마주식회사 Ｎ1-(펜에틸)-ｎ2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물
CN102698266A (zh) * 2012-05-15 2012-10-03 中国医学科学院北京协和医院 Cd200在制备系统性红斑狼疮治疗药物中的应用
CN102725264A (zh) * 2010-01-06 2012-10-10 韩诺生物制药株式会社 双胍衍生物、其制备方法以及包含其作为活性成分的药物组合物
CN102770455A (zh) * 2009-08-03 2012-11-07 迈阿密大学 用于体内扩增调节性t细胞的方法
US20130095140A1 (en) * 2011-01-07 2013-04-18 Elcelyx Therapeutics, Inc. Biguanide Compositions and Methods of Treating Metabolic Disorders
KR20140036598A (ko) * 2012-09-17 2014-03-26 가톨릭대학교 산학협력단 메트포민을 이용한 루프스를 포함하는 면역질환의 예방 또는 치료용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2610255T3 (pl) 2010-08-25 2016-08-31 Neopharm Co Ltd Związki 1H-benzo[d]imidazol-5-ilowe i kompozycja do leczenia chorób zapalnych
KR101432246B1 (ko) * 2011-09-20 2014-08-21 가톨릭대학교 산학협력단 메포민을 포함하는 자가면역질환 예방 및 치료용 조성물
KR101613371B1 (ko) * 2014-11-10 2016-04-18 가톨릭대학교 산학협력단 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060635A (en) * 1975-03-31 1977-11-29 William H. Rorer, Inc. Amidinoureas for treating diarrhea
US4183956A (en) * 1975-11-05 1980-01-15 William H. Rorer, Inc. Method for treating gastrointestinal spasms, gastrointestinal hyperacidity and hypertensive disorders with amidinoureas
WO2003084475A2 (en) * 2002-03-29 2003-10-16 University Of Maryland, Baltimore INHIBITORS OF THE S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF INHIBITING CANCER EMPLOYING THE SAME
WO2003089601A2 (en) * 2002-04-17 2003-10-30 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
US20110053941A1 (en) * 2007-11-30 2011-03-03 Newlink Genetics IDO Inhibitors
CN102770455A (zh) * 2009-08-03 2012-11-07 迈阿密大学 用于体内扩增调节性t细胞的方法
KR20110053837A (ko) * 2009-11-16 2011-05-24 한올바이오파마주식회사 Ｎ1-(펜에틸)-ｎ2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물
CN102725264A (zh) * 2010-01-06 2012-10-10 韩诺生物制药株式会社 双胍衍生物、其制备方法以及包含其作为活性成分的药物组合物
US20130095140A1 (en) * 2011-01-07 2013-04-18 Elcelyx Therapeutics, Inc. Biguanide Compositions and Methods of Treating Metabolic Disorders
CN102698266A (zh) * 2012-05-15 2012-10-03 中国医学科学院北京协和医院 Cd200在制备系统性红斑狼疮治疗药物中的应用
KR20140036598A (ko) * 2012-09-17 2014-03-26 가톨릭대학교 산학협력단 메트포민을 이용한 루프스를 포함하는 면역질환의 예방 또는 치료용 조성물

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
F. H. S. CURD等: "Synthetic Antimalarials. Part I V. 2-Phenylguanidino-4-aminoalkylamino-6-methylpyrirnidines", 《JOURNAL OF THE CHEMICAL》 *
H. C. CARRINGTO等: "Synthetic Antimalarials. Part XLIX .* The Structure and Xynthesis of the Dihydrotriaxine Metabolite of Proguanil", 《JOURNAL OF THE CHEMICAL SOCIETY》 *
RICHARD A. GLENNON等: "Arylguanidine and Arylbiguanide Binding at 5-HT3 Serotonin Receptors: A QSAR Study", 《BIOORGANIC & MEDICINAL CHEMISTRY》 *
SEYMOUR L. SHAPIR等: "Hypoglycemic Agents. II. Arylbiguanides", 《JOURNAL OF THE AMERICAN CHEMICAL SOCIETY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111566084A (zh) * 2017-09-05 2020-08-21 北京强新生物科技有限公司 中枢神经系统疾病的新疗法
CN111566084B (zh) * 2017-09-05 2022-12-20 北京强新生物科技有限公司 中枢神经系统疾病的新疗法
CN116253666A (zh) * 2017-09-05 2023-06-13 北京强新生物科技有限公司 中枢神经系统疾病的新疗法
CN113194936A (zh) * 2018-11-07 2021-07-30 加图立大学校产学协力团 含新型化合物和钙调磷酸酶抑制剂的用于预防和治疗移植排斥反应或移植排斥疾病的组合物

Also Published As

Publication number Publication date
US20180118668A1 (en) 2018-05-03
EP3130582A1 (en) 2017-02-15
EP3130582B1 (en) 2018-10-10
KR20150124923A (ko) 2015-11-06
EP3130582B8 (en) 2019-01-02
EP3130582A4 (en) 2017-08-30
US10100006B2 (en) 2018-10-16
ES2702337T3 (es) 2019-02-28
US20170114008A1 (en) 2017-04-27
AU2015254037B2 (en) 2019-03-21
JP6462002B2 (ja) 2019-01-30
KR101705446B1 (ko) 2017-02-09
AU2015254037A1 (en) 2016-11-17
CN111407753A (zh) 2020-07-14
JP2017519723A (ja) 2017-07-20
CA2946516C (en) 2022-02-01
CA2946516A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
CN106458869A (zh) 具有免疫疾病治疗效果的新型化合物及其应用
US10716771B2 (en) Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient
AU2014244744B2 (en) Pharmaceutical composition for inhibiting immune response through inducing differentiation into regulator T cells and promoting proliferation of regulator T cells
KR101613371B1 (ko) 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도
JP2019501183A (ja) 調節ｔ細胞媒介性疾患の予防または治療用薬学的組成物
KR20190045513A (ko) Sd282 화합물 또는 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 후 면역 질환의 예방 및 치료용 조성물
WO2017142014A1 (ja) 炎症性疾患を対象とした医薬
KR20130106320A (ko) 골수유래억제세포를 유효성분으로 포함하는 이식거부반응 또는 자가면역질환의 예방 또는 치료용 조성물
KR20130106786A (ko) 골수유래억제세포 및 레바미피드를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
KR101273747B1 (ko) Ｓｔａ-21을 유효성분으로 함유하는 관절염의 예방 및 치료용 조성물
RU2597976C2 (ru) Способ получения регуляторных дендритных клеток
KR20170141914A (ko) 베르바민을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
KR101627046B1 (ko) 메트포민, 코엔자임 q10 및 스타틴을 유효성분으로 포함하는 복합제제 및 이의 면역질환 치료를 위한 용도
KR102372552B1 (ko) 알파리포익산 및 메트포민을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
KR102366937B1 (ko) 3,3`-디인돌릴메탄을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
JP2024510403A (ja) 敗血症の新しい治療法
HK40067371B (zh) 具有比人外周血的自然杀伤细胞更高水平的自然细胞毒性受体、杀伤活性及γ-干扰素生产能力的记忆样自然杀伤细胞的制备方法
HK40067371A (zh) 具有比人外周血的自然杀伤细胞更高水平的自然细胞毒性受体、杀伤活性及γ-干扰素生产能力的记忆样自然杀伤细胞的制备方法
KR20160052220A (ko) 타크롤리무스 및 비타민d를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170222

RJ01 Rejection of invention patent application after publication